Zacks Investment Research downgraded shares of BioLineRx Ltd. (NASDAQ:BLRX) from a buy rating to a hold rating in a research report released on Tuesday morning.

According to Zacks, “Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company’s portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases. “

BLRX has been the subject of several other research reports. Maxim Group cut BioLineRx from a buy rating to a hold rating and cut their target price for the stock from $4.00 to $1.00 in a research report on Monday, August 8th. Roth Capital reiterated a buy rating and set a $7.00 target price on shares of BioLineRx in a research report on Sunday, August 14th. Finally, S&P Equity Research cut their target price on BioLineRx from $1.24 to $1.10 in a research report on Friday, September 23rd. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company currently has a consensus rating of Buy and a consensus target price of $2.68.

Shares of BioLineRx (NASDAQ:BLRX) opened at 1.04 on Tuesday. BioLineRx has a 12 month low of $0.71 and a 12 month high of $1.73. The company’s market cap is $58.68 million. The firm has a 50-day moving average price of $1.02 and a 200 day moving average price of $0.93.

BioLineRx (NASDAQ:BLRX) last released its earnings results on Thursday, August 11th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by $0.02. Equities analysts predict that BioLineRx will post ($0.26) earnings per share for the current year.

A hedge fund recently raised its stake in BioLineRx stock. Menta Capital LLC boosted its stake in shares of BioLineRx Ltd. (NASDAQ:BLRX) by 11.7% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 98,917 shares of the company’s stock after buying an additional 10,400 shares during the period. Menta Capital LLC owned 0.18% of BioLineRx worth $101,000 as of its most recent filing with the SEC. 12.46% of the stock is owned by hedge funds and other institutional investors.

About BioLineRx

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.

5 Day Chart for NASDAQ:BLRX

Get a free copy of the Zacks research report on BioLineRx (BLRX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related companies with's FREE daily email newsletter.